Podcasts about opioids

AP correspondent Jennifer King reports on a bankruptcy judge's ruling on opioid lawsuits against Purdue Pharma.

In honor of National Safety Month, the Society of Actuaries is re-releasing its very first Research Insights podcast — a foundational conversation that still resonates today. Dale Hall, FSA, CERA, MAAA, Managing Director of Research, introduces the episode, which highlights the findings from the 2017 SOA report, "Analysis of Opioid Overdose Death Trends in the United States." This conversation explores key mortality trends, risk factors, and how actuarial analysis can support public health efforts, especially in tackling the opioid crisis. It's a timely reflection during a month dedicated to reducing preventable harm. Explore the original report here: https://www.soa.org/resources/research-reports/2017/2017-opioid-overdose-deaths-us/ Send us your feedback at ResearchInsights@soa.org

A historic and national $7.4 billion dollar settlement has been reached with Purdue Pharma, the maker of the opioid OxyContin that spurred a major start of the opioid epidemic. A prior settlement had been struck down by the Supreme Court. NPR'S national addiction correspondent, Brian Mann, joins Lisa Desjardins with more. PBS News is supported by - https://www.pbs.org/newshour/about/funders

A historic and national $7.4 billion dollar settlement has been reached with Purdue Pharma, the maker of the opioid OxyContin that spurred a major start of the opioid epidemic. A prior settlement had been struck down by the Supreme Court. NPR'S national addiction correspondent, Brian Mann, joins Lisa Desjardins with more. PBS News is supported by - https://www.pbs.org/newshour/about/funders

Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study Drug and Alcohol Dependence People who experience a nonfatal opioid overdose are at increased risk of subsequent overdose but is also a potential moment to intervene. In this cohort study, they used statewide data from Connecticut to assess differences in overdose outcomes in the year following a nonfatal overdose by treatment type received. Overall, 56% of patients received no treatment, while 35% received medication for opioid use disorder (MOUD) (25% buprenorphine and 11% methadone) and 21% received inpatient treatment (detox and/or extended inpatient). Both methadone (aHR=0.41) and buprenorphine (aHR=072) were associated with decrease in subsequent overdose, whereas neither detox nor prolonged inpatient treatment were associated with decreased overdose. These findings further support the importance of MOUD and the need to increase access to treatment in this high-risk population.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Dive into practical, evidence-based approaches to managing pain in patients with opioid use disorder, bust common myths, and explore strategies to support patients. This episode will enhance your skills in providing holistic, patient-centered care. We're joined by Dr. Jessica Merlin, @JessicaMerlinMD (University of Pittsburgh).  Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Credits Producer, Show Notes, Infographics: Carolyn Chan MD, MHS Hosts: Carolyn Chan, MD, MHS and Shawn Cohen MD Reviewer: Payel Jhoom Roy MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Jessica Merlin MD, PhD, MBA Sponsor: JournalFeed Try JournalFeed free for 7 days — and get 20% off your first year with code CURB25 at journalfeed.org/curb. Sponsor: Freed Usecode: CURB50 to get $50 off your first month when you subscribe at freed.ai Sponsor: Mint Mobile Get your summer savings and shop premium wireless plans at MINTMOBILE.com/CURB

Dive into practical, evidence-based approaches to managing pain in patients with opioid use disorder, bust common myths, and explore strategies to support patients. This episode will enhance your skills in providing holistic, patient-centered care. We're joined by Dr. Jessica Merlin, @JessicaMerlinMD (University of Pittsburgh).  Claim CME for this episode at curbsiders.vcuhealth.org! By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education. Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME! Credits Producer, Show Notes, Infographics: Carolyn Chan MD, MHS Hosts: Carolyn Chan, MD, MHS and Shawn Cohen MD Reviewer: Payel Jhoom Roy MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Jessica Merlin MD, PhD, MBA Sponsor: JournalFeed Try JournalFeed free for 7 days — and get 20% off your first year with code CURB25 at journalfeed.org/curb. Sponsor: Freed Usecode: CURB50 to get $50 off your first month when you subscribe at freed.ai Sponsor: Mint Mobile Get your summer savings and shop premium wireless plans at MINTMOBILE.com/CURB.

The Clark County Opioid Abatement Council awarded more than $5.3 million in settlement grants to local organizations, including $2.75 million for the Vancouver Bridge Shelter Project, which will offer housing and addiction recovery services. https://www.clarkcountytoday.com/news/opioid-abatement-council-awards-2-75-million-to-vancouver-bridge-shelter-project/ #Vancouver #OpioidSettlement #BridgeShelter #AddictionRecovery #ClarkCounty #PublicHealth #Homelessness #Carelon #Narcan #Prevention

In the past few years, as street drug makers increasingly cut fentanyl into drugs like cocaine, there's been a rise in overdoses among people who aren't addicted to opioids. Nashville, in particular, has seen overdoses rise among tourists. The city has worked to get overdose reversal drugs into downtown bars and music venues. We'll learn what the uptake process was like. Also: a bond market checkup and a pullback in corporate sponsorship at Pride events.

Family Reconnect Waitlist: https://www.realrecoverytalk.com/frc In this episode, we're joined by Kevin Lanning, host of The Rise Above Podcast, who shares his powerful story of recovery after nearly a decade of battling opiate addiction. Now with 7½ years clean, Kevin opens up about what it truly took for him to achieve long-term sobriety — from hitting bottom to finding purpose through service and connection. Kevin talks in detail about how working with others has been the driving force behind his recovery and how The Rise Above Podcast has helped him build meaningful relationships, spark honest conversations, and stay grounded in the principles of recovery. This is a conversation about healing, purpose, and showing up for the next person in line. If you're looking for hope and real insight into what long-term recovery looks like, don't miss this one. KEVIN YT CHANNEL: https://www.youtube.com/@UCw1nUfBMo7mO3yncTIwOpNQ KEVIN IG: https://www.instagram.com/riseabovewithkevin/ Treatment Prep Guide: https://www.realrecoverytalk.com/treatmentprep SoberLink: https://www.soberlink.com/partners-family-and-friends/rrt Join our Big Book Study! https://www.realrecoverytalk.com/bigbookstudy Join our FREE FB Support group!: https://www.facebook.com/groups/realrecoverytalk Download our free guides!: https://www.realrecoverytalk.com/guides Tom IG: https://www.instagram.com/realrecoverytalktom/ Ben IG: https://www.instagram.com/realrecoverytalkben/ RRT IG: https://www.instagram.com/realrecoverytalkpodcast/

When it comes to treating chronic pain, doctors have few options to reach for aside from opioid prescriptions for their patients. A non-opioid medication recently approved by the U.S. Food and Drug Administration stands to change that. A journalist explains how researchers discovered a new way to combat pain with this drug, which a Canadian doctor describes as “almost the holy grail.”

Send us a textWelcome back Rounds Table Listeners! Today we're introducing a new format—the first episode in our Trial Files series, where we provide an overview of a recent Trial Files issue. This week, Dr. Mike Fralick discusses three trials included in a recent throwback issue: opioids versus non-opioids for chronic pain; IV albumin for renal impairment and mortality; and omeprazole before endoscopy in patients with GI bleed. Three trials, 9 minutes, here we go!1. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Trial (00:00 - 2:46)2. Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis (2:47 - 4:50)3. Omeprazole before Endoscopy in Patients with Gastrointestinal Bleeding (4:51 - 7:39)What is Trial Files?A free monthly newsletter on practice-changing trials, delivered straight to your inbox-- sign up here! (7:40 - 8:40)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this episode of PodMD, Pain Medicine Physician & Interventional Pain Specialist Dr Akilan Velayudhan will be discussing the topic of dealing with complex pain patients on long-term opioid therapy.

Internal medicine and pediatric physician Charles LeBaron discusses his article "How the CDC's opioid rules created a crisis for chronic pain patients." Charles discusses the 2016 CDC opioid guideline, initially framed as a solution to over-prescription and overdose deaths, and critically examines its actual impact. He reveals how the guideline, despite being based on "low quality of evidence," led to widespread restrictions on opioid prescriptions by states, federal agencies, insurance companies, and pharmacies. Charles highlights the severe, unintended consequences for chronic pain patients, including increased pain, worsened quality of life, and a rise in suicides and overdoses among those whose opioid dosages were reduced or discontinued. He also touches on the devastating impact on cancer patients experiencing undertreated pain and discusses criticisms from pain specialists and the damning report by Human Rights Watch, which characterized the de facto denial of pain relief as a potential human rights violation. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Stephen Knight, founder of Dogs Matter joins our Host Heather Major for episode two of Someone You Know.  In this episode, we discuss: The story of friendship, connection and fostering of his now 18-year-old dog Jade who sparked Stephen's initial idea for Dogs Matter. How his organization uses connectedness to create a safe space for pet owners during their recovery journey. What it was like to grow up in an environment of stigma and why Stephen does not allow it to define who he is today. And the recognition Stephen received as CNN's Hero of the Year. This year, Dogs Matter is on track to help more than 2,000 dogs in Texas alone with more than 80% of those pets from the Dallas Fort Worth area. This week, Dogs Matter will be celebrating 10 years of life-saving impact, ensuring that individuals in recovery can get the help they need while knowing their beloved pets are safe and cared for with their Tails of Triumph fundraising event.  Hosted by Heather Major, Executive Director, Independence Blue Cross Foundation. Recovery is possible, and help is available. Please visit our website to learn how we are collaborating to address this crisis: www.ibxfoundation.org. TM 2025 Someone You Know®. All Rights Reserved. Disclaimers The information contained in this podcast is solely for informational purposes and should not replace advice from a medical provider when making healthcare decisions. This podcast contains opinionated content and may not reflect the opinions of any organizations this podcast is affiliated with. Nothing discussed in this podcast shall constitute or should be construed as endorsement by the Independence Blue Cross Foundation or Independence Blue Cross, LLC of any product or service discussed herein. We will discuss opioid use and opioid treatment, which may be triggering for some listeners. Listener discretion is advised. If you or someone you know is suffering from opioid addiction, please visit ibxfoundation.org/SYK. 

Caryn Mickelson, CEO of the Health and Wellness Division of the Ko-Kwel Wellness Center, joins the Exchange.

In unexpected findings New Zealand has one of the highest rates of prescribed opioid use during pregnancy, according to new research. 

In this episode, we dive deep into the critical discussion surrounding opioid use versus non-pharmacologic treatments, such as chiropractic care, for adults dealing with pain. Drawing on a landmark study that tracked trends from 2011 to 2019, he highlights both the encouraging rise in drug-free treatment options and persistent challenges, like the staggering percentage of people with chronic pain still receiving no professional care at all. Dr. Langmaid doesn't shy away from addressing the opioid epidemic's devastating impact, and he empowers chiropractors to lead the charge in offering safe, evidence-based alternatives.Episode Notes: Trends in the Use of Opioids vs Nonpharmacologic Treatments in Adults With Pain, 2011-2019The Best Objective Assessment of the Cervical Spine- Provide reliable assessments and exercises for Neuromuscular Control, Proprioception, Range of Motion, and Sensorimotor-Integration. Learn more at NeckCare.comTurncloud EHR- Minimalist design, without being sparse. Practical, yet elegant. Turncloud's design was to find the most efficient path in a day in the life of a chiropractic office. Connect with their team at www.turncloud.com Patient Pilot by The Smart Chiropractor is the fastest, easiest to generate weekly patient reactivations on autopilot…without spending any money on advertising. Click here to schedule a call with our team.Our members use research to GROW their practice. Are you interested in increasing your referrals? Discover the best chiropractic marketing you aren't currently using right here!

Sen. Bledsoe discusses FCPS' attempt to raise the occupational tax, a bipartisan bill to promote opioid recovery clears the U.S. House, Kentucky's gas tax is falling again, honoring Kentucky officers killed in the line of duty, and feeding children during the summer.

John and Andie Larson are the father-daughter duo that make up Larson Law Group. They join Jon Hansen on Let’s Get Legal to discuss their journey to creating the law firm and one of their focus being medical malpractice and opioid abuse. Plus, the trio discusses the statute of limitations on opioid overdoses and the […]

In the past few years, as street drug makers increasingly cut fentanyl into drugs like cocaine, there's been a rise in overdoses among people who aren't addicted to opioids. Nashville, in particular, has seen overdoses rise among tourists. The city has worked to get overdose reversal drugs into downtown bars and music venues. We'll learn what the uptake process was like. Also: a bond market checkup and a pullback in corporate sponsorship at Pride events.

This PER® featured podcast includes a discussion with 3 experts on best practices for integrating opioid-sparing strategies into the treatment paradigm along with updates including the 2025 NOPAIN Act. The panel includes members of the care team including the surgical oncologist and anesthesiologist. This program is designed to help clinicians recognize the impact and potential harm of widespread opioid use for pain management following breast cancer surgeries and identify and understand strategies that can be implemented to mitigate the use of opioids to improve patient outcomes.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com Innovative technology solutions designed for behavioral health providers are transforming the way care is delivered, making it more efficient and impactful. In this episode, Ben Lawrence, Director of Behavioral Health Clinic Operations, and Dr. Ben Kurian, Executive Medical Director of Risk Identification and Outreach, from Health Care Service Corporation (HCSC), discuss the RIO program's data-driven, multidisciplinary approach to behavioral and medical health comorbidities. They tackle the challenges of opioid management and untreated depression. Lawrence and Dr. Kurian address outreach and member engagement hurdles, exploring digital methods while adhering to privacy laws. Their active partnership with the American College of Surgeons promotes non-opioid pain management strategies, demonstrating their commitment to evolving care. Tune in to learn how HCSC's innovative digital solutions are shaping the future of behavioral health care, improving provider engagement, and enhancing patient outcomes. Resources: Connect with and follow Dr. Ben Kurian on LinkedIn. Connect with and follow Ben Lawrence on LinkedIn. Follow Health Care Service Corporation on LinkedIn and explore their website. 

Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons  Scientific Reports This study compared memory performance in patients treated with methadone or buprenorphine for drug abuse to healthy controls using the Wechsler Memory Scale. Healthy controls performed better than both treatment groups in mental control. Methadone patients scored higher than controls in personal and general information, while buprenorphine patients scored lower in associate learning. Longer buprenorphine treatment was linked to better overall memory scores, and patients on methadone for over two years showed better awareness of place and time compared to long-term buprenorphine users. Overall, neither medication showed major negative effects on memory except for mental control, which was impaired in both groups. Buprenorphine appeared to better preserve memory function over time than methadone.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Send us a textIf you haven't heard of Hope Center, check out this week's podcast.  Hope Center is wonderful ministry that is worthy of your prayers and support!  Hope Center is doing glorious work across the globe, for men and women who struggle with addiction.  Special Guest:  Mark Hall - (919) 210-4421https://www.hopecm.com/www.LeagueOfLogic.com

In this episode of EMRA*Cast's “Vacation Gone Deadly: Toxins in Paradise,” hosts Maiya Smith, MD, and Lauren Rosenfeld, MD, speak with Kenneth Katz, MD, a toxicologist and practicing EM physician at Lehigh Valley Health, about toxins you might encounter while traveling, inspired by Season Three of The White Lotus. 

Connect with Tara :@burn.the.stigma0:00 Intro 0:07 Massachusetts 1:48 Strict catholic 3:00 Human breatherliser 4:10 End of life cancer care 5:00 Overdose death 7:08 It wasn't a sloppy drug 7:20It got unmanageable 8:00 Academic probation9:05 Suboxone10:50 Rehab 12:00 From pills to heroin 13:20 My 20s in rehab 14:15 Your not surrendering enough 15:15 Get out of your will 15:47 Sober living 16:40 I would end up picking up 17:30 Service commitments 18:15 5 brothers overdosed 19:00 ADHD20:00 Your powerful 22:00 You never truly finish 12 step 23:10 Cannabis doctors 24:20 Bank robbery 25:20 Federal half way house 26:40 Engaged 27:00 He didn't care 28:50 we would dabble a little bit 29:35 How do you make peace 30:45 Lifestyle of drugs 31:10 Euphoria 32:10 Cutting back , switching drugs 33:38 Ladder goals 35:00 If I take one hit 36:00 It helps me with nausea 37:10 processing feelings 38:10 prevention39:10 isolation 40:45 Shame 41:25 Motivation42:05 Boundaries 43:35 Evaluation 44:10 I wasn't good at anything 45:40 Harmful side of 12 step 47:10 Narkan 47:50 Evidence based treatment

On this edition of Parallax Views, former CDC epidemiologist and physician Dr. Charles LeBaron joins us to discuss his explosive new book Greed to Do Good: The Untold Story of CDC's Disastrous War on Opioids. Drawing on his rare vantage point as a public health insider (with 28 years' experience at the CDC), clinician, and former pain patient, Dr. LeBaron argues that the CDC's 2016 opioid guidelines—meant to reduce overdose deaths—actually worsened the crisis. We explore how flawed data, political pressure, and a rigid, arguably even at times psuedo-scientific approach led to a policy that criminalized both doctors and patients, neglected the realities of chronic pain, and contributed to the ongoing epidemic of overdose deaths. Dr. LeBaron explains why the distinction between addiction and use of opioids as a legitimate chronic pain treatment matter, how voluntary guidelines became de facto law, and why Dr. LeBaron still sees value in the CDC as an institution and is not using the book to delegitimize it (ie: critique isn't alway for tearing down, but calling for reform).. This is a powerful and challenging conversation about public health, institutional accountability, and the human cost of well-intentioned but disastrous policy.

Join this episode of The Breakdown podcast for an eye-opening conversation on opioid reform with Dr. Asif M. Ilyas, Hand & Wrist surgeon at Rothman Orthopaedics and President of the Rothman Opioid Foundation. Discover how Dr. Ilyas and the Foundation are leading efforts to curb overprescribing, educate providers, and protect patients. Watch now to learn how real change is happening. To schedule a consult with Dr. Ilyas, visit RothmanOrtho.com.

This episode of County Conversations focuses on how counties can fight the opioid epidemic and reduce stigma around substance use disorders. NYSAC Multimedia Specialist Kate Pierce-Nimz is joined by Cheryl Moore, Independent Consultant at Opioid Consulting, and Amanda Lucchino, Director of Business Development at Trellis Marketing. They discuss how counties can effectively engage residents in opioid abatement efforts through personalized, data-driven public awareness campaigns.

NPR and three public radio stations in Colorado filed a lawsuit against the Trump administration today. They argue the White House’s executive order calling on the Corporation for Public Broadcasting to cease federal funding to NPR and PBS is unconstitutional. The Trump administration has made deep cuts to universities, federal agencies, and cultural and historical institutions. Their goal is to undermine information gathering and education that doesn’t support the MAGA agenda. Opioid overdose deaths dropped nearly a quarter last year, thanks in part to medicines like Narcan. But the Trump administration wants to cut funding for Narcan, and experts worry that progress will be lost.  Four East LA artists in their early 20s formed an art collective called Asco in 1972, exploring police brutality, immigration, gender, and sexuality. They’re the subject of a new documentary.

In this episode of the Friends of NPACE Podcast we are joined by Richard Petruschke the Director of US Medical & Scientific Affairs, Pain Relief at Haleon to have a conversation about the use of NSAIDs as first-line treatment and highlighting important CDC guidelines. Tune in every other Wednesday for new episodes of the Friends of NPACE Podcast on your favorite streaming platform (Spotify, Apple Music, YouTube, and Amazon Music). View the Haleon resources below: • Haleon HealthPartners: https://www.haleonhealthpartner.com/en-us/pain-relief/ • Haleon Free Samples: https://www.haleonhealthpartner.com/en-us/samples/ • HCP Resources: https://www.haleonhealthpartner.com/en-us/learning-lab/educational-resources/#pain-relief • Patient Resources: https://www.haleonhealthpartner.com/en-us/patient-care-resources/#pain-relief • Nonopioid Pain Management portal: https://www.haleonhealthpartner.com/en-us/pain-relief/conditions/nonopioid-pain-management/overview/ • Continuing Education: https://www.haleonhealthpartner.com/en-us/news-events/#pain-relief • Pain Portfolio Product Pages: https://www.haleonhealthpartner.com/en-us/pain-relief/brands/ • Pain Relief Coupon: https://www.haleonhealthpartner.com/en-us/patient-care-resources/pain-relief-coupon-handout/

This blog was created using Notebook LM.This podcast describes the FDA approval of Suzetrigine, a novel non-opioid medication intended for moderate to severe pain. It explains that Suzetrigine operates by inhibiting voltage-gated sodium channel 1.8, which are crucial for transmitting pain signals. 

On the Tuesday, May 27 edition of Georgia Today: Georgia Power pushes more fossil fuel use to accommodate data center growth; Investigators highlight the "disturbing" ways BioLab was storing dangerous chemicals; And a new painkiller could help patients avoid addiction to opioids.

Dr. Tom Brophy on the cost of opioids. full 2092 Tue, 27 May 2025 17:59:21 +0000 5MMaCpn8dRxQik46qpYTlevG7NTa6HcO news,a-newscasts,top picks Marty Griffin news,a-newscasts,top picks Dr. Tom Brophy on the cost of opioids. On-demand selections from Marty's show on Newsradio 1020 KDKA , airing weekdays from 10 a.m. to 2 p.m. 2024 © 2021 Audacy, Inc. News News News News news News News News News News False https://player.amperwavepodcasting.com?feed-link=https

Restless leg syndrome is a common movement and sleep disorder affecting 2-3% of the population. Certain neurologic disorders are associated with a higher incidence, and neuropsychiatric medications prescribed by neurologists and psychiatrists often exacerbate these symptoms. In January, the American Academy of Sleep Medicine published updated guidelines for the evaluation and treatment of RLS. The recommendations shifted from recommending the use of dopamine agonists, to prioritizing iron evaluation and supplementation, alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin), and recommending against the long-term use of dopamine agonists. The guidelines also recommend opiates for moderate-severe medication refractory RLS. Dr. Winkleman is a Professor of Psychiatry at Harvard Medical School and chief of the Sleep Disorders Clinical Research Program in the Department of Psychiatry at Massachusetts General Hospital. He is the first-author on the new guidelines, and is here to discuss these changes and what is needed to effectively change practice. He is interviewed by Dr. Kara Wyant, Clinical Assistant Professor of Neurology, University of Michigan Medical School. RLS Curbside  

Addiction Recovery Psychology: Jung, 12-Step Evolution & Depth Therapy Breakthrough with Recovery Expert

In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Bryan Hubbard, a prominent advocate for psychedelic-assisted therapies, particularly ibogaine in the treatment of opioid addiction and mental health disorders.  Find full show notes and links here: https://thethirdwave.co/podcast/episode-305/?ref=278 Update (May 2025): Days before this episode's release, the Texas House approved a Senate-backed bill to fund ibogaine research through a public-private partnership aimed at securing FDA approval. This vote marks a major milestone in the movement Bryan describes throughout this conversation. Bryan shares his journey from leading Kentucky's Opioid Abatement Advisory Commission to spearheading breakthrough ibogaine research initiatives in Texas. He articulates ibogaine's unique neurological properties, discussing how it can reset brain neurochemistry in 36 hours and potentially treat conditions from traumatic brain injury to Parkinson's disease. The conversation explores the spiritual dimensions of ibogaine experiences, the political landscape surrounding psychedelic medicine, and Bryan's ongoing efforts to medicalize ibogaine through FDA drug development trials, highlighting Texas as the next frontier for this life-saving research. W. Bryan Hubbard is the Executive Director of the American Ibogaine Initiative. He is the first and former Chairman and Executive Director of the Kentucky Opioid Abatement Advisory Commission. He concurrently served as Special Counsel to the Kentucky Attorney General's Office of Medicaid Fraud and Abuse Control and was its prior Executive Director. He served on the Kentucky Judicial Commission on Mental Health, the Kentucky Child Support Guidelines Commission, Mine Safety Review Board, and the Kentucky Office of Drug Control Policy's Recovery Ready Communities Advisory Council. He previously served as Commissioner of the Kentucky Department of Income Support wherein he led the Commonwealth's Social Security Disability and Child Support Enforcement systems. He practiced workers' compensation law representing Walmart, Tyson Foods, and Tennessee Valley Authority for sixteen years. During his practice years, he observed the predacious onset of Kentucky's Opioid Epidemic amid generational joblessness, poverty, disability, and substance use. He was raised in Virginia's coalfields and is the proud grandson of two grade-school educated coal miners on whose shoulders he stands. Highlights: Why ibogaine interrupts addiction instantly The Stanford study that changed everything Resetting brain neurochemistry in 36 hours From Parkinson's to PTSD: Ibogaine's broad applications The spiritual awakening dimension of treatment How pharmaceutical interests block breakthrough medicine Kentucky's lost opportunity: $42 million for research Texas as the new frontier for ibogaine medicalization Matrix pharmacology: Ibogaine's intelligent mechanism The political war over life-saving psychedelic medicine Episode Links Website American Ibogaine Initiative Instagram: @w_bryan_hubbard X (Formerly Twitter): @w_bryan_hubbard Linkedin Episode Sponsors: Golden Rule Mushrooms - Get a lifetime discount of 10% with code THIRDWAVE at checkout

I was told to resist drugs and violence growing up, but one of those things is a hell of a lot of fun. The only thing I can afford to eat, evidently, has arsenic in it, and will kill me soon. And, if Saudi Arabia wants to bribe our president, they're going to have to step it up a little bit. Enjoy.New episodes are released every Tuesday. If you want to interact with the show, we have a voice mailbox. Call 818-336-1146 and leave feedback, or just complain, and maybe I'll use it in a future broadcast.This episode is dedicated to the boys in the Ohio Valley.https://www.icancomplain.comTEXT THE RAINWATER HOTLINE

Send us a textEpisode Summary: Dr. Andrew Chadeayne discusses the chemistry of psilocybin and other psychedelics, their potential therapeutic applications, and the challenges of commercializing them in a shifting biotech market. The conversation delves into the complexities of magic mushroom composition, debunking myths like "lemon tekking," and uncovers the booming, unregulated alternative products industry, including kratom and synthetic psilocybin analogs sold in vape shops.About the guest: Andrew Chadeayne, PhD is a chemist who also holds a law degree, specializing in patent law. He is the founder and CEO of CaaMTech, a startup specializing in the development of novel psychedelic compounds. Chadeayne collaborates with academic labs to advance psychedelic science while navigating the commercial landscape.Discussion Points:Psilocybin is a prodrug converted to psilocin, but magic mushrooms contain other psychoactive molecules like beta-carbolines, which may enhance effects by inhibiting degradation.Chadeayne's team develops psilocin prodrugs to shorten psychedelic trips, making clinical administration more manageable without altering effects.The "lemon tek" myth—that lemon juice converts psilocybin to psilocin—is false; it enhances absorption by extracting compounds, not altering chemistry.Magic mushroom bruising indicates psilocin degradation, as oxidized psilocin forms blue, inactive dimers.The multi-billion dollar alternative products industry sells kratom and synthetic psilocybin analogs, often mislabeled, in vape shops, raising safety and regulatory concerns.Kratom's minor alkaloid, 7-hydroxymitragynine, is ~40x more potent than morphine, with no reported overdoses but high habit-forming potential.Non-hallucinogenic serotonin 2A agonists, like those developed by CaaMTech's spinout, show promise for conditions like migraines without requiring a psychedelic trip.Related episode:M&M 71: Chemistry of Magic Mushrooms, DMT Analogues, Entourage Effects in Cannabis & Fungi, Novel Psychedelic Medicines, Psychedelic Startups | Andrew Chadeayne*Not medical advice.Support the showAll episodes, show notes, transcripts, and more at the M&M Substack Affiliates: KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off Readwise: Organize and share what you read. 60 days FREE through link SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. MASA Chips—delicious tortilla chips made from organic corn & grass-fed beef tallow. No seed oils or artificial ingredients. Code MIND for 20% off For all the ways you can support my efforts

In this episode of Health Talks, we sat down with Dr. Ruchi Fitzgerald from PCC Wellness Health Center to explore the topic of treatments for substance use disorder. Specically, long-acting injectables (LAIs) and other treatments for opioid use disorder (OUD). Dr. Fitzgerald shares her clinical journey into this field, the barriers patients face in staying on treatment, and how new treatments may offer a solution by providing stability and continuity of care. We dive into how treatments work, the growing eligibility among patients, and strategies for discussing these options with those considering treatment. Dr. Fitzgerald also highlights the value of listening to individuals with lived experience and how integrating harm reduction, behavioral health, and primary care can lead to more compassionate, effective care models.

Researchers Examine Nonopioid vs. Opioid Analgesics Effectiveness after Third Molar ExtractionsBy Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/researchers-examine-nonopioid-vs-opioid-analgesics-effectiveness-after-third-molar-extractions/Need CE? Start earning CE credits today at ⁠⁠⁠⁠⁠https://rdh.tv/ce⁠⁠⁠⁠⁠Get daily dental hygiene articles at ⁠⁠⁠⁠⁠https://www.todaysrdh.com⁠⁠⁠⁠⁠ Follow Today's RDH on Facebook: ⁠⁠⁠⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠⁠⁠⁠Follow Kara RDH on Facebook: ⁠⁠⁠⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠⁠⁠⁠Follow Kara RDH on Instagram: ⁠⁠⁠⁠⁠https://www.instagram.com/kara_rdh/

David Hart isn’t necessarily one of the  people you’d expect to be critical of the $7.4 billion multi-state opioid settlement reached with drug company Purdue. For 25 years, he was the assistant attorney general at the Oregon Department of Justice until his retirement last month, and he headed the department’s opioid litigation and recovery/pharmaceutical fraud unit. One way or another, he’s represented the state in opioid litigation and negotiations since 2004. But since he’s now retired, he feels an obligation to speak out about a settlement that he says is far too lenient and favorable to the Sackler family and their company, Purdue. Hart describes their behavior in igniting and fueling the opioid crisis “the worst of the worst.” He spoke with our news partner The Lund Report about his concerns and wrote an op-ed in the Oregonian/Oregonlive. He joins us to detail his concerns and how he’s making his case to the attorneys general in Oregon and the other states involved.

Kyle Santoro, a 19-year-old filmmaker, created the documentary "Fentanyl High" to explore teenage psychology behind substance abuse after witnessing overdoses at his high school. His film takes a peer-to-peer approach to addiction education, removing stigma and creating spaces for vulnerable conversations about why teens turn to substances.Kyle and Dr Grover discuss his experiences making the film and what he has learned through making it:• Kyle began the project after a classmate overdosed in a school bathroom and administrators never acknowledged the incident• Traditional school responses to substance use often involve punishment and shame rather than compassion and understanding• Several teens who participated in making the documentary achieved sobriety through the therapeutic process of sharing their stories• Film screenings serve as community events with resources, panel discussions, and free naloxone distribution• Schools often resist hosting screenings due to fear of being labeled as having a drug problem• The documentary has been screened across multiple states creating a "domino effect" of awareness in communities• Kyle raised $75,000 to produce the film through community sponsors and organizations• Prevention efforts need more youth representation to create effective messaging that resonates with teens• The film emphasizes the importance of parents maintaining open communication with their teenagersIf you want to learn more about Kyle's film, visit fentanylhigh.com.To contact Dr. Grover: ammadeeasy@fastmail.com

Drug overdose deaths in the U.S. plunged last year to their lowest level since 2019, according to the CDC. In 2024, nationwide overdose deaths fell by nearly 30,000 from the year before, a drop of about 27 percent. There were declines across all categories of drug use, including opioids, the source of most overdose deaths over the past decade. John Yang discussed more with Brian Mann of NPR. PBS News is supported by - https://www.pbs.org/newshour/about/funders

Drug overdose deaths in the U.S. plunged last year to their lowest level since 2019, according to the CDC. In 2024, nationwide overdose deaths fell by nearly 30,000 from the year before, a drop of about 27 percent. There were declines across all categories of drug use, including opioids, the source of most overdose deaths over the past decade. John Yang discussed more with Brian Mann of NPR. PBS News is supported by - https://www.pbs.org/newshour/about/funders

3pm: Guest - Tom Feegle - Beond.US - Ibogaine Therapy Clinic in Cancun // Ibogaine Therapy is breaking new ground in treating opioid addiction, PTSD and Traumatic Brain Injuries… PERMANENTLY // Twiggy Curley has Joined the Family! // 56% of pet owners would cut their own lives short to extend their pet’s, survey finds // John’s Plan to build a mini-sailboat for his cellphone

Like so many other Americans, Chris Cella fell out of the middle class and became an opioid addict. Here's how he came back. (00:00): Introduction (02:00) Cella's Opioid Addiction (09:00): Gateway Drugs Are a Real Concern (24:57) Burning Down the Entourage House (39:25) What It's Really Like in Rehab Paid partnerships with: Identity Guard: Get a 30-day free trial and over 60% off when you sign up a https://IdentityGuard.com/Tucker Tecovas: Get 10% off at tecovas.com/tucker Learn more about your ad choices. Visit megaphone.fm/adchoices

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Sean Mackey is a professor of pain medicine at Stanford University and the director of the Stanford Systems Neuroscience and Pain Lab, where his research explores the neural mechanisms of pain and the development of novel treatments for chronic pain. In this episode, Sean joins Peter for a wide-ranging discussion on the multifaceted nature of pain—as both a sensory and emotional experience—and its evolutionary purpose as a critical survival mechanism. He dives into how pain is transmitted through the nervous system, the different types of pain, and why different individuals perceive pain so differently. Sean shares insights into pain management strategies ranging from medications like NSAIDs and opioids to neuromodulation techniques such as transcutaneous electrical nerve stimulation (TENS). Additionally, this episode explores the interplay between sleep and chronic pain and the psychological and emotional dimensions of pain, and it includes a personal story from Peter about his own experience with pain and how Sean's expertise helped him more than two decades ago. We discuss: The definition of pain, and how our understanding of pain has evolved from a simplistic body-mind separation to a nuanced biopsychosocial model [2:30]; The biological mechanisms behind how we perceive pain [9:30]; The role of consciousness in the perception of pain, and how nociception functions during unconscious states [14:30]; The four types of pain [22:00]; Using fMRI to identify objective biomarkers of pain in the brain [31:30]; The evolutionary role of pain in human behavior and survival [36:00]; How the brain processes and modulates pain signals, Gate Control Theory, the variability in individuals' pain perception, and effectiveness of neuromodulation techniques like TENS [41:00]; The brain's influence on pain: the role of emotion, beliefs, sleep, and individual differences in perception and tolerance [53:45]; Peter's personal journey with chronic back pain, and how the emotional consequences of pain can be more distressing than the pain itself [1:04:30]; The pharmacology of common pain medications—NSAIDs, COX-2 inhibitors, and acetaminophen [1:09:30]; Muscle relaxants: benefits, drawbacks, and personalized strategies [1:20:30]; The definition of chronic pain [1:29:15]; The role of antidepressants in pain management [1:30:15]; Opioids: their controversial and nuanced role in pain management [1:33:45]; Alternative therapies: acupuncture and cannabis [1:54:15]; Fibromyalgia and chronic pain: clinical features, brain mechanisms, and emerging treatments like low-dose naltrexone [2:01:00]; Possible brain benefits of low-dose naltrexone (LDN) for people with mild cognitive impairment [2:15:00]; Peter's recovery from severe chronic pain—how he went from immobility and high-dose opioids to full functionality [2:20:15]; Breaking the pain cycle: how physical rehabilitation and psychological recovery work together in chronic pain treatment [2:30:45]; Sean's struggle with cluster headaches, and the value of knowledge, preparation, and empathy in both managing chronic pain and caring for patients [2:39:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube